Society of Nuclear Medicine and Molecular Imaging

Benefits of using 211At include:
· Does not require molecular targeted drugs
· Reduces treatment burden
· Limits adverse effects associated with systemic therapies

Read the full article here: t.co/cIW2dYKfBb

Alpha-emitters were effective and well-tolerated to treat refractory patients with DTC -- with either 2.5 or 3.5 MBq/kg, though a dose-limiting toxicity existed at 3.5 MBq/kg. Thyroglobulin was reduced 50% and uptake in radioactive iodine-avid lesions on 131I SPECT decreased.

Patients with DTC who were refractory to radioactive iodine were given a single intravenous dose of 211At-NaAt.

The study used thyroglobulin measurement, CT imaging, and 131I SPECT to evaluate patient responses.

What happens when 131I treatment stops working Some patients with recurring or metastatic differentiated thyroid cancer (DTC) stop responding to this treatment.

This first-in-human study used alpha-emitters to treat refractory patients.

jnm.snmjournals.org/content/earl...

YouTube video by Society of Nuclear Medicine and Molecular Imaging JNM Podcast Episode 13: PET-Guided Radiotherapy: Reflections?

Podcast: PET-Guided Radiotherapy: Reflections?

Listen here: youtu.be/J1mwyxSfitU?...

FEATURED: First-in-Human Study of [211At]NaAt as Targeted α-Therapy in Patients with Radioiodine-Refractory Thyroid Cancer (Alpha-T1 Trial)

Read here: jnm.snmjournals.org/content/66/1...

FEATURED: PET Imaging of System A Amino Acid Transport Detects Early Response to Immune Checkpoint Inhibitor Therapy in a Syngeneic Mouse Model

Read here: jnm.snmjournals.org/content/66/1...

Is It Really Happening? α-Therapy and Combination Strategies to Overcome Resistance and Enhance Clinical Outcomes in Prostate Cancer

Read here: jnm.snmjournals.org/content/66/1...

The State of the Art: Current Developments in Combining External-Beam Radiotherapy and 177Lu-Labeled PSMA Ligands for Prostate Cancer Treatment

Read here: jnm.snmjournals.org/content/66/1...

Discussions with Leaders: Translating Discovery into Impact with Caius Radu

Read here: jnm.snmjournals.org/content/66/1...

The holidays must be here early, because the newest issue of The Journal of Nuclear Medicine is out now! Check out the highlights as our gift to you: jnm.snmjournals.org/content/66/12

Being able to personalize a patient's treatment is one of the cornerstones of nuclear medicine, but how are we able to do that? PET-Guided radiotherapy is one answer. Learn more about when to use it in Episode 14 of the JNM Podcast: youtu.be/J1mwyxSfitU

A 100% Complete Response Rate Shows Promise--85% of mice also achieved histologic cure. 1 and 2-cycle treatments were equally effective and well-tolerated. In the patient xenograft, a single 225Ac treatment achieved a 60% response and prolonged survival compared to no treatment.

Though previous studies have shown that HER2-targeted radiotherapies with the alpha-particle-emitting radionuclide 225Ac were effective, they were not safe for patients, as 225Ac was retained in the body, causing high toxicity.

Pre-treating a tumor before delivering alpha-radioimmunotherapy has the potential to cure human epidermal growth factor receptor 2 (HER2)-positive breast cancer.

jnm.snmjournals.org/content/earl...

FEATURED: CXCR4 PET/CT Predicts Left Ventricular Recovery 8 Months After Acute Myocardial Infarction: jnm.snmjournals.org/content/66/1...

FEATURED: 225Ac α-Pretargeted Radioimmunotherapy of Human Epidermal Growth Factor Receptor 2–Expressing Breast Cancer: jnm.snmjournals.org/content/66/1...

The State of the Art: Comparison, Agreement, and Significance Cutoffs of 18F-Flurpiridaz PET Myocardial Blood Flow Quantitation Methods and Software Packages: jnm.snmjournals.org/content/66/1...

Discussions with Leaders: Translating Research Amidst Transnational Quarrels: jnm.snmjournals.org/content/66/1...

It's November — the season of giving thanks — for a new issue of JNM! Here's what's inside this month: 🧵👇

jnm.snmjournals.org

Have you been hearing about Pluvicto in the news? Our patient accounts share more about what it is and how it works:

PET imaging reveals which patients will (or will not) recover after heart attack CXCR4 PET/CT imaging of inflammation predicts recovery, guides therapy

A new approach to PET #imaging published by @snm-mi.bsky.social offers a promising way for physicians to identify patients at risk for poor functional recovery after a #heartattack. #nuclearmedicine

Heart attacks affect nearly one million Americans each year, but what happens after—the healing process—is less well understood. A new PET imaging technique has changed that. Read more in this month’s JNM: jnm.snmjournals.org/content/earl...

🚀 Don’t Miss Your Chance to Apply!

The Alavi Mars Shot Research Awards through SNMMI offer 5 grants of $110,000 each to advance infection & inflammation imaging.

Apply by Oct 30, 2025!

sites.snmmi.org/MarsShot/?_z...

Today for Nuclear Medicine Week, we wanted to give a special shoutout to the 326 nuclear pharmacists who are key in the advancement of our field - particularly for increased access to theranostics. Thank you for your vital contributions!

From atoms to AI-provided answers? The SNMMI AI Task Force is exploring how artificial intelligence can help physician workflow. What task would you give to AI for more patient face time? Let us know 👇

Such great timing!

From Atoms to Answers Celebrating the Power of Nuclear Medicine Happy Nuclear Medicine Week! Nuclear medicine is transforming the way we understand, diagnose, and treat disease. This year's theme -- "From Atoms to Answers" -- celebrates the members of this field,...

Happy Nuclear Medicine Week! Nuclear medicine is transforming the way we understand, diagnose, and treat disease. This year's theme -- "From Atoms to Answers" -- celebrates the members of this field from the lab to patients' bedsides.

snmmi.org/Web/News/Art...

Join Us in Celebrating Nuclear Medicine Week!

It's time to recognize all the hard work this community does. Join us by sharing your stories, photos, and videos of your work and celebrations!

YouTube video by Society of Nuclear Medicine and Molecular Imaging Biomarkers in Prostate Cancer: What's in the Blood?

PODCAST: Biomarkers in Prostate Cancer: What's in the blood? 👉 youtu.be/IpaEwpSA2kY?...